Effects of cystic fibrosis medication on lung and pancreas health in young children
Official title: Pulmonary and pancreatic response to cystic fibrosis modulator therapy in young children
Funded at Emory University · NIH-11088841 · Data updated 2026-11-12
This study is looking at how a new medication for cystic fibrosis can help the lungs and pancreas of young kids aged 2 to 5, with the hope of preventing lung problems and improving how their pancreas works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $621,136 |
| NIH project number | 5R01HL173340-02 |
| Project ID | NIH-11088841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are young children aged 2 to 5 years diagnosed with cystic fibrosis.
✕Less likely to help
Patients older than 5 years or those without a cystic fibrosis diagnosis may not receive any benefit from this research.
What this research studies
This research investigates how a new medication for cystic fibrosis, known as highly effective modulator therapy (HEMT), affects the lungs and pancreas in young children aged 2 to 5 years. The study aims to understand whether this therapy can prevent lung disease progression and improve pancreatic function, which is often compromised in cystic fibrosis. By monitoring the health of these children over time, researchers hope to identify the benefits of early treatment with this medication. The approach includes assessing pulmonary function and pancreatic health through clinical evaluations and tests.
Why it matters
Potential benefit: If successful, this research could lead to improved lung and pancreatic health in young children with cystic fibrosis, potentially reducing the severity of the disease.
How similar studies have gone: Previous research has shown promising results with similar therapies in older patients, but this specific approach in young children is relatively novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Stecenko, Arlene a — Emory University
- Study coordinator: Stecenko, Arlene a
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.